Home › Companies › HALOZYME THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and HALOZYME THERAPEUTICS INC.’s Form 8-K, filed 2024-04-26 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore HALOZYME THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are HALOZYME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-04-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Barbara Duncan | 90,120,424 | 15,016,536 | 161,704 | -- | 10,383,116 | Majority: yes |
| Elect Director: Mahesh Krishnan, M.D. | 103,968,663 | 1,164,017 | 165,984 | -- | 10,383,116 | Majority: yes |
| Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: | 102,860,435 | 2,190,603 | 247,626 | -- | 10,383,116 | Passed |
| Proposal 3: The vote on a proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers was as follows: | 91,512,252 | 13,612,616 | 173,796 | -- | 10,383,116 | Passed |
| Proposal 4: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows: | 114,912,469 | 647,868 | 121,443 | -- | -- | Passed |
This meeting is also recorded here as 2024-04-26; both records come from the same filing, so the date should be checked against it.
Source: HALOZYME THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-04-26 — read the filing on EDGAR.
Each item below shows how the 434 asset managers that disclosed a HALOZYME THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of HALOZYME THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2024-04-25.
Combines 18 wordings of this item as funds reported it.
98% Passed · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:”): 102,860,435 for, 2,190,603 against — passed, per its Form 8-K filed 2024-04-26 (Item 5.07). Of all 127,186,000 outstanding shares: 81% for, 2% against (83% of the company cast a for/against vote).
The 426 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 15,390,332 | 997 | 0 | 0 | For |
| Vanguard | 15,269,471 | 0 | 0 | 0 | For |
| State Street | 8,962,675 | 0 | 0 | 0 | For |
| Artisan | 5,263,684 | 0 | 0 | 0 | For |
| New York Life | 5,075,256 | 0 | 0 | 0 | For |
| AllianceBernstein | 4,458,885 | 0 | 0 | 0 | For |
| JPMorgan | 4,152,435 | 0 | 0 | 0 | For |
| SNYDER CAPITAL MANAGEMENT L P | 3,592,472 | 0 | 0 | 0 | For |
| Charles Schwab | 3,479,747 | 0 | 0 | 0 | For |
| Thrivent | 3,420,634 | 0 | 0 | 0 | For |
| Fidelity | 3,301,960 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,941,522 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,197,574 | 0 | 0 | 0 | For |
| Invesco | 2,188,543 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 1,890,859 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 1,849,642 | 0 | 0 | 0 | For |
| Nuveen | 1,736,289 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| American Century | 1,385,470 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,378,187 | 0 | 0 | 0 | For |
| First Trust | 1,212,386 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,166,281 | 0 | 0 | 0 | For |
| Dimensional | 1,148,873 | 0 | 0 | 0 | For |
| Epoch Investment Partners, Inc. | 1,146,048 | 0 | 0 | 0 | For |
Showing the 25 largest of 426 asset managers. See all 426 in the interactive database.
Meeting held 2024-04-25.
Combines 5 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Barbara Duncan”): 90,120,424 for, 15,016,536 against, per its Form 8-K filed 2024-04-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 127,186,000 outstanding shares: 71% for, 12% against (83% of the company cast a for/against vote).
The 122 asset managers below cast 87% of the shares they voted on this item FOR (52,576,135 for, 7,776,543 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,892,835 | 0 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 3,209,068 | 44,852 | 0 | 0 | For |
| State Street | 58,372 | 2,768,522 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 2,076,163 | 0 | 0 | Against |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 1,623,745 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 0 | 1,004,224 | 0 | 0 | Against |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 455,295 | 340,856 | 0 | 0 | For |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 144,234 | 413,107 | 61,921 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 372,820 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2024-04-25.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mahesh Krishnan, M.D.”): 103,968,663 for, 1,164,017 against, per its Form 8-K filed 2024-04-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 127,186,000 outstanding shares: 82% for, 1.0% against (83% of the company cast a for/against vote).
The 122 asset managers below cast 99.5% of the shares they voted on this item FOR (60,091,787 for, 260,891 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,892,835 | 0 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 3,209,068 | 44,852 | 0 | 0 | For |
| State Street | 2,826,894 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 1,623,745 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 1,004,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 796,151 | 0 | 0 | 0 | For |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 557,341 | 0 | 61,921 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 372,820 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2024-04-25.
Combines 6 wordings of this item as funds reported it.
87% Passed · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The vote on a proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers was as follows:”): 91,512,252 for, 13,612,616 against — passed, per its Form 8-K filed 2024-04-26 (Item 5.07). Of all 127,186,000 outstanding shares: 72% for, 11% against (83% of the company cast a for/against vote).
The 122 asset managers below cast 92% of the shares they voted on this item FOR (55,677,455 for, 4,675,989 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,782,699 | 1,110,136 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 2,961,922 | 291,998 | 0 | 0 | For |
| State Street | 2,826,749 | 145 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 1,623,745 | 0 | 0 | Against |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 1,004,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 628,733 | 167,418 | 0 | 0 | For |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 557,341 | 0 | 61,921 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 0 | 372,820 | 0 | 0 | Against |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2024-04-25.
Combines 6 wordings of this item as funds reported it.
99.4% Passed · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Proposal 4: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows:”): 114,912,469 for, 647,868 against — passed, per its Form 8-K filed 2024-04-26 (Item 5.07). Of all 127,186,000 outstanding shares: 90% for, 0.6% against (91% of the company cast a for/against vote).
The 122 asset managers below cast 99.9% of the shares they voted on this item FOR (60,309,472 for, 43,972 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,892,835 | 0 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 3,253,920 | 0 | 0 | 0 | For |
| State Street | 2,826,749 | 145 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 1,623,745 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 1,004,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 796,151 | 0 | 0 | 0 | For |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 557,341 | 0 | 61,921 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 372,820 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2024-04-25.
99.4% Passed · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Proposal 4: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows:”): 114,912,469 for, 647,868 against — passed, per its Form 8-K filed 2024-04-26 (Item 5.07). Of all 127,186,000 outstanding shares: 90% for, 0.6% against (91% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (46,783 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BERNZOTT CAPITAL ADVISORS | 46,360 | 0 | 0 | 0 | For |
| Two Roads Shared Trust | 423 | 0 | 0 | 0 | For |
Meeting held 2025-05-01 (outside the 2023-2024 season's 1 July to 30 June window; reported in this season's filings).
96% Passed · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:”): 98,252,464 for, 3,966,034 against — passed, per its Form 8-K filed 2025-05-02 (Item 5.07). Of all 127,186,000 outstanding shares: 77% for, 3% against (80% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (60 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Weil Company, Inc. | 40 | 0 | 0 | 0 | For |
| Freedom Day Solutions, LLC | 20 | 0 | 0 | 0 | For |
Ranked by the number of HALOZYME THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 127,186,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 12.10% |
| 2 | Vanguard | 12.01% |
| 3 | State Street | 7.05% |
| 4 | Artisan | 4.14% |
| 5 | New York Life | 3.99% |
| 6 | AllianceBernstein | 3.51% |
| 7 | JPMorgan | 3.26% |
| 8 | SNYDER CAPITAL MANAGEMENT L P | 2.82% |
| 9 | Charles Schwab | 2.74% |
| 10 | Thrivent | 2.69% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 10.11% | 13F |
| Vanguard Group | 9.14% | 13F |
| Artisan Partners Limited Partnership | 5.26% | DEF14A |
| State Street | 5.10% | 13F |
| Geode Capital | 2.38% | 13F |
| Helen I. Torley | 1.89% | DEF14A |
| Invesco | 1.64% | 13F |
| Northern Trust | 1.41% | 13F |
| Morgan Stanley | 1.37% | 13F |
| Dimensional Fund Advisors | 1.33% | 13F |
Percentages above are of 127,186,000 shares outstanding, as reported by HALOZYME THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HALOZYME THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At HALOZYME THERAPEUTICS INC.'s shareholder meeting held 2024-04-25, in the 2023-2024 proxy season, 434 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,020 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — the proposal passed with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: HALOZYME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-04-26.
HALOZYME THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.